Importance of Aggressively Modifying LDL Cholesterol in Clinical Practice

In the podcast, Dr. Pam Togham highlights the significance of lowering LDL cholesterol and the need for aggressive risk modification. Despite the availability of multiple therapies, clinical practice often falls short in achieving target LDL levels recommended by guidelines. Statin monotherapy, the traditional approach, is no longer sufficient. Dr. Togham emphasizes the importance of combination therapy and alternative options like Bempedoic acid for patients unable to tolerate statins. The breakthrough study of clear outcomes demonstrates the efficacy of Bempedoic acid in reducing mace events, LDL cholesterol, and high sensitive CRP levels. This study provides an effective non-statin option for high-risk patients.